Would you favor an adjuvant anti-PD-1 inhibitor or dabrafenib/trametinib for stage IIIC/D resected BRAF V600K-mutated cutaneous melanoma?

I think it depends on the pt’s preference and tolerability of side effects. The Combi-Ad and KEYNOTE-054 adjuvant trials have shown a similar reduction in the recurrence risk (around 50%). They, however, have very different side effect profiles. With immunotherapy, the chief concerns of my patients ...

There are no good, randomized controlled trials in the adjuvant setting for melanoma to answer this question conclusively. But extrapolating from the data in the metastatic setting, where it is quite clear that the "immunotherapy first" approach affords a benefit over the targeted therapy first appr...